Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Interferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immune-evasion. Patients featuring MET amplification, a genetic lesion driving transformation, may benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interferon-γ modulation of PD-L1/PD-L2 in MET-amplified tumours.
Pubmed ID: 30723303
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A commercial antibody vendor, specializing in secondary antibodies.
View all literature mentionsCell line MKN45 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentions